Special Issue: Aging and Rejuvenation

Review

Aging, Clonality, and Rejuvenation of Hematopoietic Stem Cells

Shailaja Akunuru¹,* and Hartmut Geiger¹,²,³,*

Aging is associated with reduced organ function and increased disease incidence. Hematopoietic stem cell (HSC) aging driven by both cell intrinsic and extrinsic factors is linked to impaired HSC self-renewal and regeneration, aging-associated immune remodeling, and increased leukemia incidence. Compromised DNA damage responses and the increased production of reactive oxygen species (ROS) have been previously causatively attributed to HSC aging. However, recent paradigm-shifting concepts, such as global epigenetic and cytoskeletal polarity shifts, cellular senescence, as well as the clonal selection of HSCs upon aging, provide new insights into HSC aging mechanisms. Rejuvenating agents that can reprogram the epigenetic status of aged HSCs or senolytic drugs that selectively deplete senescent cells provide promising translational avenues for attenuating hematopoietic aging and, potentially, alleviating aging-associated immune remodeling and myeloid malignancies.

Stem Cells and Aging

Aging is associated with a gradual functional decline of a variety of organs and tissues and is the highest risk factor for cancer [1,2]. With the onset of a demographic shift towards an older population, understanding the mechanisms regulating the complex process of aging is important for understanding aging-associated disease development and promoting a longer and healthier lifespan. Over the past decade, it has become evident that organ aging is linked to the aging-associated decline in somatic stem cell function in various animal model systems [3–11]. Stem cells, with self-renewal and multi-lineage differentiation properties, generate distinct tissue-specific cell types during development and later support homeostatic maintenance and tissue repair. During aging, cells are continuously exposed to both cell-intrinsic and -extrinsic stress factors; the effects of stress on long-lasting stem cells can cause damage accumulation and impair long-term tissue homeostasis. The hematopoietic system depends on the constant replenishment of differentiated blood cells by HSCs and hematopoietic progenitor cells (HPCs) throughout adulthood, a process termed ‘hematopoiesis’. In this review, we focus on HSC aging and discuss novel research, including age-associated HSC cytoskeletal protein polarity shifts (see Glossary) and global epigenetic drifts, that add exciting new insights into HSC aging mechanisms. We further discuss how these might contribute to recently discovered common changes in aging-associated clonal dynamics and conclude with the likely implications and limitations of HSC rejuvenation clinical approaches.

Aging of HSC

Adult mammalian hematopoietic tissue homeostasis depends on the balance of HSC self-renewal with multi-lineage differentiation decisions [12,13]. Under steady-state hematopoiesis,
HSCs differentiate within the bone marrow (BM) into myeloid and lymphoid progenitors, leading to the balanced and tightly controlled production of both myeloid and lymphoid lineages. By contrast, older adults present with a higher prevalence of anemia and compromised adaptive immunity due to reduced T and B lymphocyte function caused by thymus involution and to a decreased number and/or function of aged lymphoid progenitors [14,15]. This aging-associated impairment in immunity was initially anticipated to be a consequence of reduced numbers of HSCs. Evolutionary theories on hematopoietic aging support a model in which an early peak in lymphocyte production in life is a program favored by natural selection and a decline over time is inevitable, whereas an additional decline in HSCs and lymphoid progenitor fitness further contributes to aging-associated immune remodeling [16]. Interestingly, HSC numbers are increased two–threefold in C57Bl/6 aged mice (>20-months old) relative to young mice and are only slightly decreased in the aged mouse strains DBA/2 and Balb/c [9,17–20]. These mouse-strain differences can be advantageously exploited through forward genetics to identify genetic regulators of HSC aging [21]. More recent publications on human HSC aging further support the view that phenotypic human HSC frequency in BM (CD34+CD38 CD90+ cells) is more likely to be increased, not decreased, upon aging [22,23]. While phenotypic mouse HSC numbers are elevated upon aging, their function is impaired, as demonstrated by their reduced transplantation efficiency in competitive transplantation assays. Using irradiated animals as recipients, aged mouse HSCs (23–28 months) exhibit reduced repopulation capacity, independent of murine genetic background [3,24–27]. In addition, aged mouse HSCs display reduced BM homing abilities [20,28], and adhesion to BM stroma cells, as well as increased granulocyte colony-stimulating factor (G-CSF)-induced mobilization [29]. Similarly, HSCs isolated from BM of older human donors (45 years and above) have been associated with reduced transplantation success in patients, indicating that human HSC regenerative capacity also declines upon aging [30].

Another aging-associated phenotype characteristic of HSCs is their myeloid-biased differentiation potential, described by the propensity of aged HSCs to contribute to a higher percentage of myeloid cells in peripheral blood, both upon transplantation and at steady state. This property is also reflected by a relative expansion of myeloid progenitor numbers in aged compared with young mice (Figure 1, Key Figure). This feature of aged HSCs is demonstrated to be a cell-autonomous function [3,31]. Dorshkind et al. proposed an interesting evolutionary hypothesis to explain the aging-associated loss of lymphoid progenitor cells whereby the energy-inefficient process of antigen receptor rearrangement is minimized to conserve energy [14,32]. They suggested this process would reduce the risk of transformations caused by DNA cleavage and ligation during V(D)J rearrangement, when lymphoid progenitors are highly susceptible to chromosomal translocations and transformation, particularly in an aged microenvironment [14]. Consistent with this theory is the fact that pediatric hematopoietic malignancies largely represent lymphoid leukemias, while older individuals, in addition to presenting a high frequency of chronic lymphocytic leukemia (CLL), also exhibit a higher incidence of myeloid malignancies, such as myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Aged human HSCs also exhibit reduced lymphoid potential, although an associated myeloid lineage increase is still a matter of debate [22,23]. A myeloid-biased HSC lineage fate might be directly linked to increased myeloid leukemia, given that the transcriptional profile and epigenetic changes in aged mouse HSCs show a significant overlap with those of leukemic stem cells [33]. Consistently, young (1–2-month-old) mouse BM cells transduced with the BCR-ABL oncogene, an oncogene linked to chronic myelogenous leukemia (CML), develop a lymphoid disease (defined by both CD19 expression and blast morphology in spleen cells) upon transplantation, whereas older BM cells can manifest as either CML or myeloid leukemia, further supporting the idea that an aging-associated HSC myeloid bias exists [34]. More recently, aging of the mouse HSC microenvironment, or niche, was found to contribute to HSC aging and myeloid skewing, in part via increased levels of the chemokine RANTES, secreted from the aged niche [35]. In these studies,

**Glossary**

**Antigen receptor rearrangement/VDJ rearrangement:** genes encoding variable (V), Diversity (D), and Junciton (J) regions of either B cell receptor (BCR) and antibodies (B cells) or antigen-recognizing T cell receptor (TCR) (T cells) undergo rearrangements to generate a highly diverse repertoire of antibodies and TCRs for effective antigen recognition and immunity.

**BCR-ABL:** chromosomal translocation commonly detected in chronic myelogenous leukemia (CML) generated by the fusion of the BCR gene from chromosome 22 and the ABL kinase domain from chromosome 9, generating the fusion protein BCR-ABL with constitutively active tyrosine kinase activity.

**Cell autonomous function:** changes in function driven by cell intrinsic changes independent of cell extrinsic factors.

**Clonality:** HSCs have been historically deemed homogenous in their contribution to hematopoiesis during steady state or injury. However, recent experiments identified the relative contribution of individual HSC to hematopoiesis changes with aging, resulting in an increased clonal distribution with aging.

**Competitive transplantation:** a gold standard experiment to test the function of HSCs. Hematopoietic stem/progenitor cells (HSPCs) or total bone marrow (BM) cells are transplanted along with fixed numbers of competitors (wild-type/normal BM) cells. Subsequently, the HSPC contribution to differentiated blood cells in the BM and blood is monitored, testing for HSPC function.

**Cytoskeletal protein polarity:** asymmetric versus symmetric distribution of cytoskeletal proteins in the cytoplasm of a stem cell (in this case).

**Epigenetic drift:** epigenetic modifications are heritable post-translational modifications of either histones or DNA itself without alterations in the DNA sequence. Global changes in the epigenetic profile of stem cells upon aging are termed ‘epigenetic drift’.

**FOXO transcription factors:** FOXO, a family of Forkhead transcription factors, have a critical role in regulating longevity in model organisms and in stress response signaling.
ex vivo treatment of HSCs with RANTES resulted in fewer T cell progeny, and Rantec-knockout mice rescued the aging-associated myeloid-biased lineage differentiation. Moreover, computational modeling approaches, in combination with transplantation experiments, have established a critical link between niche aging and an indirect induction of HSC aging [16,36,37]. Combined, these studies imply that both HSC cell intrinsic and extrinsic aging-associated changes contribute to the altered HSC lineage potential and function with age.

Mechanisms Contributing to HSC Aging and Disease

Environmental (such as aging microenvironment, niche interactions, or radiation) and cell-intrinsic stress (such as metabolic and replicative stress), along with altered stress responses in aged HSCs, result in DNA damage and an increased frequency of genomic mutations [38]. In several tissues, aging-associated genomic mutations have been associated with cancer development, including leukemia [1].

An Altered DNA Damage Response

Aging-associated cancer incidence has long been associated with a compromised DNA damage response (DDR). Quiescent HSCs can utilize nonhomologous end joining, an error-prone DNA repair pathway that compromises genomic integrity and leads to chromosomal translocations and fusion genes [39]. The association between DNA repair pathways, aging, and genomic instability stems from studies of diseases such as Fanconi anemia (FA), where cells are defective for DNA repair pathways. Patients with FA and FANCD1-deficient mice present with BM failure and increased cancer incidence [40]. Further evidence for DNA damage pathways impacting HSC function has been derived from studies in mice with defective DNA repair pathways. These mouse HSCs have been shown to exhibit reduced reconstitution ability and self-renewal, and to ultimately undergo stem cell exhaustion [41]. However, one of the striking characteristics of ‘DNA repair pathway’-deficient mice is a decreased number of HSCs from increased apoptosis and decreased proliferation. This contrasts with the observation that HSC numbers increase upon aging, suggesting that the molecular mechanisms driving HSC aging are not solely driven by defective DNA damage pathways. It has been shown that aged HSCs present elevated DNA damage markers, such as two–threefold more γH2AX foci and ‘elongated tails’ in comet assays, which are used as surrogate markers for double-stranded breaks and DNA damage [41–44]. One caveat to these studies is that they were performed in germ-free laboratory mice lacking additional environmental stress factors. Second, these conclusions were largely based on γH2AX foci formation as a DNA damage ‘marker’, although γH2AX foci are also associated with stalled replication forks and ribosomal biogenesis [44], bringing into question the idea that aged HSCs have more DNA damage than young HSCs. Finally, Moehrle et al. recently demonstrated in vivo that aged HSCs repair double-strand breaks as efficiently as young HSCs without accumulating additional DNA mutations [43], data that further question the impact of aging on hematopoietic genetic instability. Consequently, additional studies are warranted to investigate to what extent DDR and impaired genomic integrity impact HSC aging.

ROS

Maintaining appropriate levels of ROS (oxidative stressors) is implicated in cellular aging (Box 1). Indeed, maintaining a delicate balance between ROS generators and quenchers has been shown to be critical for HSC maintenance and DNA integrity, as well as for preventing ROS-mediated damage to cells [45]. HSCs are quiescent, have an inherently low metabolism rate, and generate low levels of ROS. However, upon aging, ROS levels accumulate and can result in ROS-induced oxidative free radical damage [46]. Emphasizing the significance of ROS levels in HSC activity, Jang et al. isolated ROSlow and ROShigh mouse HSCs and demonstrated that ROSlow HSCs retained their long-term self-renewal activity, while ROShigh HSCs failed to serially transplant [47]. Treatment of HSCs with the ROS inhibitor N-acetyl cysteine (NAC) or with a p38 MAPKinase inhibitor (an intrinsic cellular stress signal in response to ROS) rescued ROShigh HSC
colony formation, demonstrating a role of ROS and p38 MAPK in ROS-mediated HSC maintenance [47]. Additional evidence for the ROS regulation of HSC activity stems from a series of studies on the Forkhead O (FOXO) subfamily of transcription factors. Mice with a hematopoietic-specific deletion of Foxo1, Foxo3a, and Foxo4 present with fewer HSCs and progenitors and increased ROS levels than control mice [48,49]. In these murine studies, ROS-high HSCs did not display elevated levels of DNA damage, suggesting a likely role for ROS in cell signaling rather than in DNA damage in its contribution to HSC exhaustion upon aging.
Mitochondria maintain mitochondrial DNA (mtDNA), which is regulated separately from nuclear DNA. ROS generated from mitochondrial respiration (metabolic ROS) are in close proximity to mtDNA and can elicit, under certain circumstances, oxidative mtDNA damage. Interestingly, little is reported on mtDNA repair systems and whether aging has an impact. mtDNA mutations drive premature aging-like phenotypes in mouse HSCs, but not HSC physiological aging phenotypes [50], demonstrating that mtDNA damage does not causally contribute to HSC aging. As documented for HSCs, mtDNA mutation frequencies are increased in several other human tissues (such as eye, skeletal muscle, heart, and neurons) and are most likely due to oxidative damage [51–53]. Recently, more mtDNA mutations altering mitochondrial function have been detected in fibroblasts, blood, and fibroblast-derived iPSCs of aged individuals (60–72 years) compared with younger controls (25–50 years) [54].

Compromised DDR and increased ROS levels resulting in DNA or mtDNA mutations have been historically considered as primary HSC aging pathways. However, recent revolutionizing concepts in the field, including changes in aging-associated global epigenetics, protein polarity shifts, HSC senescence, and clonal selection, add essential insights into HSC aging mechanisms.

Global Epigenetic Shifts and Changes in Polarity
Comparative transcriptional profiles of young and aged HSCs indicate that, in aged HSCs, myeloid differentiation linked genes, such as Runx1, Hoxb6, and Osmr, are upregulated, while lymphopoiesis genes are downregulated [24]. These global gene expression changes are in accordance with age-induced myeloid skewing at the level of gene transcription and also raise the interesting possibility that aging is a consequence of altered epigenetic transcriptional regulation. Indeed, several laboratories have reported changes in the global epigenetic profile of aged mouse HSCs [33,55–57].

DNA methylation is an epigenetic marker largely associated with gene repression. By gene ontology (GO) analysis of aged HSCs, Sun et al. found that regulatory gene regions associated with HSC differentiation were hypermethylated, while genes associated with regulating HSC maintenance were hypomethylated [55], consistent with impaired differentiation potential and increased numbers of aged HSC. Other studies have demonstrated aging-associated hypermethylation of HSC genes regulated by the polycomb repressive complex 2 (PRC2) as well as genes regulated by repressive H3K27Me3 histone modifications [42,56]. For example, genome-wide promoter occupancy of activation-associated H3K4Me3 and repressive H3K27Me3 histone marks has been described for aged HSCs, correlating with the transcriptional activity of affected loci [55]. These aging-associated epigenetic changes include changes in both repressive and active marks without a directional genome-wide shift towards activation or repression upon aging, leading researchers to coin the term ‘epigenetic drift’ or ‘shift’. Further evidence for an aging-associated HSC epigenetic shift stems indirectly from comparative gene expression analyses, demonstrating deregulation of several components of chromatin organization and epigenetic maintenance genes in aged mouse HSCs, including genes of the PRC2 complex [58]. Finally, Tom Mistelli’s laboratory recently revealed that regions of high

---

Box 1. Reactive Oxygen Species

ROS are generated by, among others, oxidative phosphorylation and, thus, result from regular cellular metabolism. ROS levels are also increased by external stimuli, such as inflammation, ultraviolet (UV), radiation, and chemotherapy. Prolonged exposure to ROS and ROS-generated free radicals has been proposed to contribute to aging [84] via oxidation of DNA, RNA, and proteins. Oxidized DNA products result in DNA damage that triggers a DNA damage repair response and, in cases of incomplete repair, senescence and apoptosis are initiated, which result in reduced HSC numbers and functionality. However, ROS are also critical mediators of cell signaling. Thus, maintaining appropriate levels of ROS through a delicate balance between ROS generators and ROS quenchers is critical for HSC maintenance, DNA integrity, and ROS-mediated damage to cells [46].
H3K4methylation in translocation prone regions of human HSCs facilitate chromosomal breakage and increased translocation frequency [59]. This suggests that epigenetic drift also predisposes aged HSCs to acquire distinct genomic translocations, a hypothesis that awaits experimental verification.

In another study, Florian et al. demonstrated a significant decrease in aged mouse HSC acetylated histone 4 on lysine 16 (H4K16Ac) cellular levels, which is associated with active gene expression. Surprisingly, H4K16Ac also exhibits altered nuclear spatial distribution (polar in young and apolar in aged HSCs) that is controlled by aging-associated elevated activity of the small RhoGTPase, Cdc42 [57]. A switch from canonical to noncanonical Wnt signaling (Wnt5a) has also been shown to result in the elevated activity of Cdc42 in aged HSCs and, interestingly, ex vivo Wnt5a treatment of young HSCs can induce an aged HSC phenotype [60]. Inhibition of elevated Cdc42 activity with the pharmacological inhibitor CASIN was found to increase H4K16Ac levels and restore its polar spatial distribution in aged mouse HSCs, correlating with their rejuvenated function [57]. Collectively, these studies imply that changes in the appearance and nuclear spatial distribution of epigenetic marks can contribute to epigenetic drift with aging.

HSC Clonal Contribution to Hematopoietic Aging

Hematopoiesis is regarded as a polyclonal event with the perception that most HSCs are equipotent when contributing to hematopoiesis through life, and that multiple clones may be activated to support blood production. HSCs are clearly heterogeneous with respect to function and activity in limiting dilution transplantation experiments [3,31]. However, paradigm-shifting research on HSC clonality and the heterogeneous contribution of HSC clones to hematopoiesis has recently challenged this view. Higher levels of clonality, where only a few clones actively contribute to the production of peripheral blood cells, has been observed with hematopoietic aging [61–63]. Historically, an aging-related progression towards hematopoietic clonality is demonstrated by skewing towards individual X-chromosome inactivation associated with myeloid bias in aged female individuals [64,65]. Two recent studies tracked mouse HSC clonality in situ by either utilizing sleeping beauty transposase-mediated mobilization of genomic transposons, or Tie2-Cre-mediated YFP labeling of HSCs, monitoring both steady-state and stress-induced hematopoiesis. Using quasi-random insertional labeling of mouse HSCs in a transplantation model (during regeneration), Sun et al. demonstrated that multiple clones could contribute to hematopoiesis during development, although, later in adulthood, long-lived progenitors (rather than HSCs) were mostly contributing to hematopoiesis [62]. A surprising finding was that granulopoiesis could be polyclonal, while lymphopoiesis seemed to be mono- or oligoclonal in young animals, even during steady state [62]. By performing limiting dilution clonal tracking experiments in vivo, Busch et al. similarly concluded that short-term HSCs could contribute to steady-state hematopoiesis during adulthood; these short-term HSCs were thought to increase the direct contribution of HSCs to hematopoiesis with aging [63]. The authors further implied, based on sophisticated mathematical models, that the aging-associated myeloid bias might be a consequence of reduced multipotent progenitor (MPP) flux to common lymphoid progenitors (CLP) rather than a change in the HSC pool composition [63]. Verovskaya et al., using cellular barcoding and high-throughput sequencing to monitor clonal contribution to regenerative hematopoiesis, concluded that young mice present fewer active HSC clones producing high numbers of progeny, while in aged mice more active HSC clones are observed, but which produce fewer progeny [61]. These findings appear contradictory, but one explanation might be that clonality in steady-state hematopoiesis might differ from clonality in a regenerative setting, such as BM transplantation. To reconcile these findings, another potential explanation could be that, upon aging, the HSC pool increases, along with the potential for diversity and clonality. However, this HSC pool might not contribute to hematopoiesis in vivo and their progeny might thus not be observed in peripheral blood. Clonality further needs to be experimentally addressed both directly at the level of HSCs, and with respect to the active contribution of HSCs to the peripheral blood pool.
Recently, several groups have identified somatic mutations in blood cells of healthy older adults using large data sets from high-throughput targeted sequencing methodologies [66–68]. Such somatic DNA mutations are rare, but they are also detected in younger individuals. They increase in frequency upon aging, reaching approximately 10–20% of the clonal contribution in individuals aged 65–85 years [67,68]. Interestingly, clonal hematopoiesis in these older adults has been largely associated with mutations in only three genes, implying a causal relation for these genes in aging-associated clonality: DNMT3a, a DNA methyltransferase enzyme; TET2, a DNA demethylase; and ASXL1, polycomb group (PcG) protein, a transcriptional repressor. Mutations in these genes have also been associated with MDS and AML [67,68]. DNMT3a, Tet2, and ASXL1 encode proteins that epigenetically regulate transcription, raising an interesting novel hypothesis of ‘epigenetic clonality’ with aging, where clones with certain epigenetic profiles are preferentially maintained by the aging microenvironment. McKerrell et al. detected DNMT3a and JAK2 mutations, as well as mutations in spliceosome genes, such as SF3B1 and SRSF2, in healthy adults [66]. Of note, DNMT3a and JAK2-associated HSC clonal expansion was found to be linear with age, while mutations in the spliceosome genes were linked to an exponential clonal expansion occurring after 70 years of age, implying that the aged environment could preferentially select for spliceosome-defective clones [66,69]. Thus, HSC aging, aging-associated genomic instability, epigenetic shifts and clonality, as well as disease development are complex interwoven processes that appear to be causally linked to HSC aging and aging-associated changes in hematopoiesis.

In conclusion, compromised DNA damage and increased ROS levels are believed to contribute to HSC aging and aging-associated diseases, but direct evidence for such associations is absent. Instead, recent research supports the idea that these factors are, more than likely, not directly involved in aging and aging-associated diseases affecting HSCs. Novel findings rather suggest a prominent role of changes in the epigenetic landscape and polarity of HSCs with aging. Clonality shifts are also a likely novel hallmark of aging in the hematopoietic system and in aging-associated diseases, such as certain forms of leukemia. Moreover, the hypothesis that epigenetic and polarity shifts drive HSC aging is further supported by the mechanisms that promote HSC rejuvenation, as discussed below.

**HSC Rejuvenation**

The concept of stem cell rejuvenation is tightly linked to the finding that differentiated cells can be reprogrammed into induced pluripotent stem cells (iPSCs). This suggests that the differentiated, and perhaps aged, state, might also be reversible by changing the epigenetic landscape. Wahliest et al. demonstrated that iPSCs generated from aged murine HSCs that were redifferentiated back into HSCs were functionally highly similar to young HSCs, suggesting that HSC aging is driven, at least in part, by reversible epigenetic reprogramming [70]. Additional evidence that stem cell rejuvenation is possible has emerged from mouse caloric restriction studies. Caloric restriction extends the lifespan of multiple organisms, including worms, flies, and mice [71]. Prolonged fasting has been found to rejuvenate the aging-associated myeloid differentiation bias, as well as the reduced long-term repopulation capacity of aged mouse HSCs. Such rejuvenation has been mechanistically attributed to reduced IGF-1 signaling and restored youthful levels of intrinsic HSC nutrient sensing [72]. Sirtuins, which are mitochondrial histone deacetylases, mediate caloric restriction effects in lower organisms, such asSaccharomyces cerevisiae, Caenorhabditis elegans, and Drosophila melanogaster [73]. In particular, Sirt3, a mammalian sirtuin that regulates the mitochondrial acetylation landscape, has been found to be reduced in aged mouse HSCs; furthermore, Sirt3 overexpression has been reported to rescue aging-associated HSC functional defects [74]. Expression of Sirt7 has also been shown to be decreased in aged murine HSCs, while its overexpression has been found to increase HSC reconstitution capacity and to reduce the aged HSC myeloid bias [75]. This effect was probably mediated by the mitochondrial unfolded protein response, UPRmt, a signaling...
pathway that regulates mitochondrial chaperon transcription and is critical for stress relief [75]. Altogether, these studies highlight an interesting role of caloric restriction and sirtuins in HSC aging and rejuvenation.

The expression of another nutrient-sensing protein, the mammalian target of rapamycin (mTOR), has been reported as elevated in aged murine HSCs [76] and treatment with the mTOR inhibitor rapamycin has been found to reverse the aging-associated increase in HSC numbers, restoring reconstitution potential and self-renewal [76]. Transient treatment of aged mice with rapamycin was also shown to improve the vaccination response to influenza virus [76], implying that improved lymphopoiesis and adaptive immunity ensue in response to mTOR inhibition.

Another recent example of successful HSC rejuvenation comes from studies on a specific inhibitor of Cdc42 activity (CASIN) [57]. As discussed previously, CASIN treatment ex vivo can restore aged mouse HSC phenotypes by both regulating Cdc42 activity and epigenetic reprogramming by elevating H4K16Ac levels to those of young cells, again emphasizing the strong link between epigenetic reprogramming and stem cell rejuvenation. Further supporting the role of epigenetic reprogramming in HSC rejuvenation, Satoh et al. identified that aging-associated immunosenescence could be linked to a reduced expression of Satb1, an epigenetic regulator of lymphoid progenitors [77]. Moreover, overexpression of Satb1 via epigenetic reprogramming could rescue aged HSC immunosenescence [77]. Thus, multiple successful approaches currently share a common underlying theme: epigenetic reprogramming appears to be a central mechanistic contributor to HSC rejuvenation (Figure 2).

Figure 2. Rejuvenation of Hematopoietic Stem Cells (HSCs) and Potential Pitfalls. N-acetyl cysteine (NAC) treatment and Sirtuin 3 (Sirt3) overexpression rejuvenate old HSCs by reducing reactive oxygen species (ROS) levels. Wnt5a treatment results in aging of HSCs by both altering cytoskeletal protein polarity and causing global epigenetic changes. The Cdc42 inhibitor CASIN can rejuvenate old HSCs by reverting both the cytoskeletal polarity shift and the epigenetic landscape to a young state in HSCs. Other HSC-rejuvenating agents and/or approaches, such as CASIN treatment, Satb1, Sirt3 overexpression, and senolytic drug treatment, might be partially able to revert aging-associated clonality to a level seen in a young hematopoietic system. However, in general, rejuvenating agents might not be able to revert DNA mutations in HSCs associated with clonality upon aging (the rejuvenating agent potential limitation is depicted by an orange box; the blue arrow indicates aging and the pink arrow indicates rejuvenation).
Box 2. Clinician’s Corner

Rejuvenation and reprogramming of hematopoietic stem cells might improve the adaptive immune response in older organisms and alleviate aging-associated myeloid malignancies.

The combination of senolytic drugs, such as ABT263, or of epigenetic modulators, such as CASIN, might provide rejuvenation of both cell-extrinsic and intrinsic factors that contribute to HSC aging.

Current research on rejuvenating agents that address aging-associated changes intrinsic to HSCs might have potential clinical applications for the ex vivo treatment of BM from aged donors, to improve transplantation success rates.

Current limitations in harvesting HSC rejuvenation agents for in vivo clinical scenarios are still not well defined because of unanswered questions, including: (i) what is the contribution of damaged DNA to HSC aging? And (ii) what happens to DNA mutations following HSC rejuvenation?

Cellular senescence represents an irreversible state of growth arrest, which is a well-established cancer defense mechanism in solid tissues associated with aging and aging-associated diseases. The senescence-associated secretory phenotype (SASP) that senescent cells display refers to the secretion of inflammatory cytokines, matrix metalloproteases, chemokines, and growth factors with aging-associated tissue damage and cancer promotion [78–80]. Expression of the cyclin-dependent kinase (CDK) inhibitor p16 (Ink4a) is a critical step for establishing and maintaining cellular senescence [81]. Consequently, p16ink4a-positive senescent cells in aged mouse tissues, such as skeletal muscle, white adipose tissue, kidney, spleen, and liver, appear to shorten healthy lifespan [81]. Depletion of senescent cells within tissues was recently accomplished in a transgenic mouse model that expresses FK-506-binding protein caspase 8 fusion protein under control of the Ink4a promoter. Addition of dimerizer-activated caspase 8 was shown to kill senescent cells upon binding FK-506-BP in Ink4a-positive cells. These mice presented an extended lifespan with improved kidney, skeletal muscle, and heart function, as well as decreased incidence of sarcomas, and an overall increase in cancer-free survival [81]. Most interesting was the fact that depleting senescent cells using the senolytic drug ABT263 directly in the BM of aged mice, significantly improved the function of aged HSC in serial transplant experiments [82]. These cells exhibited reduced myeloid bias and improved long-term transplantation ability. Consequently, it would be of particular interest to test whether senolytic drugs, such as ABT263, might alleviate the initiation of aging-associated leukemia (Box 2.

Table 1. HSC Rejuvenation Pathways and Agents

<table>
<thead>
<tr>
<th>Pathway Category</th>
<th>Rejuvenation agent and/or approach</th>
<th>Rejuvenated HSC function</th>
<th>Mechanism</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrient sensing</td>
<td>Caloric restriction</td>
<td>Myeloid bias; long-term repopulation; chemoprotection</td>
<td>IGF-1</td>
<td>[72]</td>
</tr>
<tr>
<td></td>
<td>Sirt3 overexpression</td>
<td>Long-term repopulation; competitive repopulation</td>
<td>ROS mitochondrial function</td>
<td>[74]</td>
</tr>
<tr>
<td></td>
<td>Rapamycin</td>
<td>HSC numbers; competitive repopulation; immune suppression</td>
<td>mTOR</td>
<td>[76]</td>
</tr>
<tr>
<td>Epigenetic modulators</td>
<td>CASIN</td>
<td>Myeloid bias; competitive long-term repopulation</td>
<td>Cdc42; H4K16 acetylation</td>
<td>[57]</td>
</tr>
<tr>
<td></td>
<td>Satb1</td>
<td>Myeloid bias; immune suppression</td>
<td>Lymphoid progenitor gene expression</td>
<td>[77]</td>
</tr>
<tr>
<td>Senescence depletion</td>
<td>ABT263</td>
<td>Myeloid bias; competitive long-term repopulation</td>
<td>BCL2- and BCL-xl-mediated apoptosis; senescent cell depletion</td>
<td>[82]</td>
</tr>
</tbody>
</table>
Figure 2, and Table 1). These studies further imply a specific role for tissue-resident senescent cells in conferring aging on distinct types of cell, including HSCs.

Concluding Remarks
The availability of rejuvenating agents that target different mechanisms involved in reprogramming the aged hematopoietic system and HSCs back to a youthful status demonstrate that aging, in biological terms, is amendable, and that attenuation of HSC aging is possible (Table 1). If HSC epigenetic drift drives aging and clonality (epigenetic clonality), the use of epigenetic reprogramming agents, such as CASIN and the Satb1 activator, might restore a more homogeneous epigenetic profile in aged HSCs and rejuvenate the HSC pool. Interestingly, epigenetic reprogramming agents might also be effective rejuvenating agents even in the scenario of DNMT3a-, ASXL1-, and TET2-mutant HSC clones, by directly affecting the misregulated epigenetic targets. This view is supported by the clinical success of epigenetic modulating agents, such as azacitidine, in aging-associated diseases such as MDS and AML [83]. However, the efficacy of these rejuvenating agents might be limited by the relative age of HSCs and by the extent of changes that have already taken place upon aging. Successful rejuvenation approaches target changes in HSCs that are biologically reversible. Given that DNA mutations are not reversible, it is not clear whether a rejuvenation approach would affect HSCs with DNA mutations. Age-related accumulation of DNA mutations might pose a challenging limitation to these rejuvenation approaches and would require further study to determine whether aging becomes irreversible at a certain age (see Outstanding Questions).

The agents discussed thus far largely address HSC intrinsic rejuvenation pathways and not the critical role of the microenvironment and stem cell niche aging. Senescent cell depletion might be a promising approach to address the aging microenvironment and revert an aging-associated precancerous state by not only depleting senescent cells, but also by reducing SASP and SASP-induced changes in the microenvironment (Box 2). In conclusion, rejuvenating agents might provide a promising tool for rejuvenating aged HSCs and rigorous testing of these agents either individually or in combination is warranted in preclinical human HSC aging models. Such approaches might allow the clinical development of pharmacological drugs to support healthy hematopoietic aging.

Acknowledgments
S.A. is supported by an Edward P. Evans foundation and a T32CA117846-08A1 grant. H.G. is supported by the Edward P. Evans Foundation, NIH grants HL076604, DK077762, AG040118, and the DFG SFB 1074 and 1149, the BMBF, the Excellence program of the Baden-Württemberg Foundation, and the European Commission (FP7 Marie Curie Initial Training Network MARRIAGE). We thank Leesa Sampson for comments.

References

Outstanding Questions
During HSC aging, are protein polarity changes and epigenetic drifts just associations or are they mechanistically connected?

What is the role if any, of mitochondrial mutations in the pathogenesis of aging-associated leukemias?

How do rejuvenating agents affect the functional reversal of aged lymphoid progenitors?

Do rejuvenating agents target genomic instability in the aged bone marrow and, if so, how?

Rejuvenation agents so far address stem cell intrinsic properties. However, it is important to tackle how the aged microenvironment handles and/or supports rejuvenated cells.

What age is the right age for a rejuvenation process? When is rejuvenation too late or irreversible?
33. Beerman, I. et al. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging, Cell Stem Cell 12, 413–425
42. Beerman, I. et al. (2014) Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. Cell Stem Cell 15, 37–50
56. Taivo, O. et al. (2013) DNA methylation analysis of murine hematopoietic side population cells during aging. Epigenetics 8, 1114–1122
69. Rozhok, A.I. et al. (2014) Stochastic modeling indicates that aging and somatic evolution in the hematopoietic system are driven by non-cell-autonomous processes. Aging (Albany NY) 6, 1033–1048
70. Wahlestedt, C. et al. (2013) An epigenetic component of hematopoietic stem cell aging amenable to reprogramming into a young state. Blood. 121, 4257–4264